Objective: In this retrospective study, we shared our single-center experience of the outcomes of patients who had previously received breast cancer treatment and developed acute myeloid leukemia. Patients and Methods: Ten female acute myeloid leukemia (AML) patients followed in the Hematology Department of Erciyes University between 2013 and 2020 were included in the study. Results: All of the patients had been diagnosed with invasive ductal carcinoma in the past. Eight (80%) patients received chemoradiotherapy, while two patients received only chemotherapy. Anthracycline-based treatments were administered to all patients as chemotherapy. The median time between the diagnosis of breast cancer and the diagnosis of acute leukemia was 52 months (7-110). As induction therapy, 7 (70%) patients received idarubicin and cytarabine, and 1 patient received azacitidine. Complete remission was achieved in half of the patients after the first induction. Four (40%) patients underwent allogeneic transplantation from a fully matched sibling donor. Eight (80%) patients died. The most common cause of death was disease recurrence. Two patients are still being followed in remission. The median follow-up time after acute leukemia was 14 months (0.9-86 months).Conclusion: Treatment related AML is a feared outcome after breast cancer treatment. Detection of breast cancer at an early stage will reduce the risk of t-AML as it will reduce the exposure of patients to intensive chemotherapy and radiotherapy. Every patient treated for breast cancer should be followed closely and carefully for t-AML.